GEN Exclusives

More »

GEN News Highlights

More »
May 23, 2011

Institute for Genome Sciences and OpGen to Create Database of Microbial Sequences

  • The University of Maryland Institute for Genome Sciences (IGS) and OpGen say that they will work together to develop a database of high-quality, finished, annotated microbial sequences. OpGen, a whole-genome DNA analysis company, will provide optical maps and sequence finishing technology.

    The company's Argus™ Optical Mapping System and MapIt® Services provide high-resolution, whole-genome restriction maps for sequence assembly and finishing, strain typing, as well as comparative genomics. The technology does not use gel-based, PCR-based, or sequencing-based methodology.

    “We are using this technology for validation of our de novo sequencing projects and anticipate that these will serve as an extraordinary set of reference organism templates to be used by the large number of resequencing efforts worldwide,” says Claire Frasier-Liggett, Ph.D., director of IGS and professor of medicine, microbiology, and immunology at the University of Maryland School of Medicine.

    IGS will provide clinically characterized microbial samples and sequencing data from microbial genomics studies including from NIH's Human Microbiome Project (HMP) and from research by the NIAID Genomic Sequencing Center for Infectious Diseases (GSCID) on campus.

    Last year IGS secured a five-year contract from NIAID to establish a genome sequencing center. It will be one of three such centers nationwide; the others are at the J. Craig Venter Institute and The Broad Institute.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?